Chapter 3: Use of ESAs and other agents* to treat anemia in CKD

Kidney International Supplements

Volumn 2, Issue 4, 2012, Pages 299-310

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85096646483     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2012.35     Document Type: Article

References (88)

1. National Kidney Foundation, KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 (2006), S1–S146.
2. National Kidney Foundation, KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 (2007), 471–530.
3. National Kidney Foundation, KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Section III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis 47 (2006), S86–108.
4. Bernhardt, W.M., Wiesener, M.S., Scigalla, P., et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21 (2010), 2151–2156.
5. Goodnough, L.T., Brecher, M.E., Kanter, M.H., et al. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med 340 (1999), 438–447.
6. MacLeod, A.M., The blood transfusion effect: clinical aspects. Immunol Lett 29 (1991), 123–126.
7. Shander, A., Sazama, K., Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 50 (2010), 1144–1155.
8. Zhou, Y.C., Cecka, J.M., Sensitization in renal transplantation. Clin Transpl, 1991, 313–323.
9. Levin, A., Thompson, C.R., Ethier, J., et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34 (1999), 125–134.
10. Foley, R.N., Parfrey, P.S., Harnett, J.D., et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 28 (1996), 53–61.
11. Harnett, J.D., Foley, R.N., Kent, G.M., et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47 (1995), 884–890.
12. Rigatto, C., Parfrey, P., Foley, R., et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 13 (2002), 1084–1090.
13. Collins, A.J., Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl, 2002, 44–48.
14. Ofsthun, N., Labrecque, J., Lacson, E., et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63 (2003), 1908–1914.
15. Regidor, D.L., Kopple, J.D., Kovesdy, C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006), 1181–1191.
16. Goodkin, D.A., Fuller, D.S., Robinson, B.M., et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22 (2011), 358–365.
17. Besarab, A., Bolton, W.K., Browne, J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998), 584–590.
18. Parfrey, P.S., Wish, T., Quality of life in CKD patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55 (2010), 423–425.
19. Lietz, K., Lao, M., Paczek, L., et al. The impact of pretransplant erythropoietin therapy on late outcomes of renal transplantation. Ann Transplant 8 (2003), 17–24.
20. Choukroun, G., Kamar, N., Dussol, B., et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 23 (2012), 360–368.
21. Canadian Erythropoietin Study Group, Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300 (1990), 573–578.
22. Revicki, D.A., Brown, R.E., Feeny, D.H., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995), 548–554.
23. Drueke, T.B., Locatelli, F., Clyne, N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006), 2071–2084.
24. Furuland, H., Linde, T., Ahlmen, J., et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 (2003), 353–361.
25. Parfrey, P.S., Foley, R.N., Wittreich, B.H., et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005), 2180–2189.
26. Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
27. Singh, A.K., Szczech, L., Tang, K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098.
28. Foley, R.N., Curtis, B.M., Parfrey, P.S., Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol 3 (2008), 1669–1675.
29. Foley, R.N., Curtis, B.M., Parfrey, P.S., Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 4 (2009), 726–733.
30. FDA presentation at Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting. Oct, 18 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM231978.pdf, 2010.
31. Lewis, E.F., Pfeffer, M.A., Feng, A., et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol 6 (2011), 845–855.
32. Palmer, S.C., Navaneethan, S.D., Craig, J.C., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153 (2010), 23–33.
33. Gandra, S.R., Finkelstein, F.O., Bennett, A.V., et al. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 55 (2010), 519–534.
34. Johansen, K.L., Finkelstein, F.O., Revicki, D.A., et al. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55 (2010), 535–548.
35. Rizzo, J.D., Brouwers, M., Hurley, P., et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28 (2010), 4996–5010.
36. Rizzo, J.D., Brouwers, M., Hurley, P., et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116 (2010), 4045–4059.
37. Skali, H., Parving, H.H., Parfrey, P.S., et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 124 (2011), 2903–2908.
38. Warady, B.A., Ho, M., Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18 (2003), 1055–1062.
39. Mitsnefes, M.M., Kimball, T.R., Kartal, J., et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 149 (2006), 671–675.
40. Schaefer, F., Cardiac disease in children with mild-to-moderate chronic kidney disease. Curr Opin Nephrol Hypertens 17 (2008), 292–297.
41. Morris, K.P., Sharp, J., Watson, S., et al. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child 69 (1993), 580–586.
42. Gerson, A., Hwang, W., Fiorenza, J., et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44 (2004), 1017–1023.
43. Staples, A.O., Wong, C.S., Smith, J.M., et al. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 4 (2009), 48–56.
44. Solomon, S.D., Uno, H., Lewis, E.F., et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363 (2010), 1146–1155.
45. Fishbane, S., Berns, J.S., Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 (2005), 1337–1343.
46. Yang, W., Israni, R.K., Brunelli, S.M., et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18 (2007), 3164–3170.
47. Eckardt, K.U., Kim, J., Kronenberg, F., et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 21 (2010), 1765–1775.
48. Kaufman, J.S., Reda, D.J., Fye, C.L., et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339 (1998), 578–583.
49. De Schoenmakere, G., Lameire, N., Dhondt, A., et al. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 13 (1998), 1770–1775.
50. Chanu, P., Gieschke, R., Charoin, J.E., et al. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol 50 (2010), 507–520.
51. Locatelli, F., Canaud, B., Giacardy, F., et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 18 (2003), 362–369.
52. Vanrenterghem, Y., Barany, P., Mann, J.F., et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62 (2002), 2167–2175.
53. Locatelli, F., Villa, G., Messa, P., et al. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. J Nephrol 21 (2008), 412–420.
54. Pergola, P.E., Gartenberg, G., Fu, M., et al. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Clin J Am Soc Nephrol 4 (2009), 1731–1740.
55. Carrera, F., Lok, C.E., de Francisco, A., et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 25 (2010), 4009–4017.
56. Gobin, J., Cernii, A., McLean, R., et al. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 31 (2011), 113–120.
57. Boven, K., Stryker, S., Knight, J., et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67 (2005), 2346–2353.
58. Casadevall, N., Nataf, J., Viron, B., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346 (2002), 469–475.
59. Macdougall, I.C., Ashenden, M., Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 16 (2009), 117–130.
60. Locatelli, F., Baldamus, C.A., Villa, G., et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 40 (2002), 119–125.
61. Nissenson, A.R., Swan, S.K., Lindberg, J.S., et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002), 110–118.
62. Tolman, C., Richardson, D., Bartlett, C., et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 16 (2005), 1463–1470.
63. Kilpatrick, R.D., Critchlow, C.W., Fishbane, S., et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008), 1077–1083.
64. Greene, T., Daugirdas, J., Depner, T., et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of ″dose-targeting bias″. J Am Soc Nephrol 16 (2005), 3371–3380.
65. Koshy, S.M., Geary, D.F., Anemia in children with chronic kidney disease. Pediatr Nephrol 23 (2008), 209–219.
66. Bamgbola, O.F., Kaskel, F.J., Coco, M., Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24 (2009), 571–579.
67. Szczech, L.A., Barnhart, H.X., Inrig, J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74 (2008), 791–798.
68. Brookhart, M.A., Schneeweiss, S., Avorn, J., et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303 (2010), 857–864.
69. Berns, J.S., Rudnick, M.R., Cohen, R.M., A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 37 (1992), 264–267.
70. Gaughan, W.J., Liss, K.A., Dunn, S.R., et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 30 (1997), 495–500.
71. Sheashaa, H., Abdel-Razek, W., El-Husseini, A., et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron Clin Pract 99 (2005), c102–c106.
72. Bridges, K.R., Hoffman, K.E., The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem 261 (1986), 14273–14277.
73. Lipschitz, D.A., Bothwell, T.H., Seftel, H.C., et al. The role of ascorbic acid in the metabolism of storage iron. Br J Haematol 20 (1971), 155–163.
74. Deved, V., Poyah, P., James, M.T., et al. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 54 (2009), 1089–1097.
75. Shahrbanoo, K., Taziki, O., Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. Saudi J Kidney Dis Transpl 19 (2008), 933–936.
76. Attallah, N., Osman-Malik, Y., Frinak, S., et al. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47 (2006), 644–654.
77. Sezer, S., Ozdemir, F.N., Yakupoglu, U., et al. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artif Organs 26 (2002), 366–370.
78. Rossert, J., Casadevall, N., Eckardt, K.U., Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15 (2004), 398–406.
79. Eckardt, K.U., Casadevall, N., Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18 (2003), 865–869.
80. Shimizu, H., Saitoh, T., Ota, F., et al. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol 126 (2011), 114–118.
81. Casadevall, N., Cournoyer, D., Marsh, J., et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 73 (2004), 389–396.
82. Cournoyer, D., Toffelmire, E.B., Wells, G.A., et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 15 (2004), 2728–2734.
83. Macdougall, I.C., Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 20:Suppl 4 (2005), iv9–i15.
84. Verhelst, D., Rossert, J., Casadevall, N., et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363 (2004), 1768–1771.
85. Andrade, J., Taylor, P.A., Love, J.M., et al. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 20 (2005), 2548–2551.
86. Weber, G., Gross, J., Kromminga, A., et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 13 (2002), 2381–2383.
87. Macdougall, I.C., Rossert, J., Casadevall, N., et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361 (2009), 1848–1855.
88. Schellekens, H., Biosimilar therapeutics-what do we need to consider?. NDT Plus 2 (2009), i27–i36.